Throughout recent years the approach to candidates for noncardiac surgery has significantly evolved. Due to the wide diffusion of less invasive surgical approaches and the improvement in anesthetic techniques and perioperative monitoring, indications to major noncardiac surgery have been extended to individuals prone to cardiac complications.

As a result, noncardiac operations may treat disease and improve quality of life even in such categories of patients, but at the expense of cardiac mortality and morbidity, prolonged hospitalizations, and consequent costs.

About half of the 100 million/year adults undergoing noncardiac surgery worldwide are old and it is likely that the number of old patients undergoing noncardiac operations in the USA will double within the coming years (from 6 million to 12 million/year) (1, 2).

**Epidemiology: As a correct diagnosis may influence the precise estimation of the incidence of cardiac events**

It has been estimated that 500,000 to 900,000 patients suffer from fatal and nonfatal perioperative cardiovascular complications annually (2).

Excluding cardiac arrest which portends a risk of in-hospital mortality of 65% (3), the most threatening com-
Complications are represented by the wide spectrum of acute coronary syndromes. Perioperative myocardial ischemia is significantly associated with a high risk of subsequent cardiovascular events (OR: 2.8; 95%CI: 1.6-4.9), while perioperative myocardial infarction (MI) is associated with an in-hospital mortality of 15%-25% (4-8).

Unfortunately, a large proportion of ischemic episodes go undetected during surgery and in the postoperative period.

Thus, myocardial ischemia occurs undiagnosed and physicians do not administer therapy and do not program secondary prevention in patients who have suffered from perioperative unstable angina or MI. The lack of an adequate management further raises the risk of subsequent cardiac events.

The correct estimation of the perioperative incidence of myocardial ischemic events, particularly MI, is hampered by the low accuracy of the traditional diagnostic criteria (i.e. typical symptoms, electrocardiographic (ECG) modifications, elevations in plasma levels of markers of myocardial injury) (9) during and after surgery.

It has been shown that:

- Patients rarely experience angina pectoris and other ischemic symptoms immediately after surgery, because of the persistence of somatic pain secondary to surgical trauma and the effect of anesthetic and analgesic drugs (4, 5, 7).
- ST-segment changes, either on continuous monitoring or on 12-lead ECG, have been shown to have a low sensitivity and specificity (~70%). Moreover, significant ST-segment changes may resolve before the time the 12-lead ECG is repeated (1, 10).
- New Q-waves appear infrequently on 12-lead ECG because most perioperative MIs are non-transmural. Moreover, some ECG analyses are influenced by Pace-Maker rhythm, left bundle branch block or chronic ST-segment changes.
- The perioperative measurements of the creatine-kinase (CK)’s cardiac-specific subunit (CK-MB) are prone to false-positive and false-negative results (11). Thus, physicians should consider a more specific and more sensitive cardiac marker in the diagnosis of MI after surgery.
- A perioperative rise in plasma level of cardiac Troponin (cTn), has been demonstrated to be more effective than traditional diagnostic methods, such as ECG, echocardiography, and CK-MB (12).

However, it should be specified that myocardial damage in the absence of either ischemic symptoms or diagnostic ECG, may be secondary to mechanisms other than ischemia (9).

The incidence of perioperative MI, when diagnosed by elevation in cTns (12,14-27), is higher than that reported in the pre-cTns studies (<1% in the general population and 15% in high-risk patients undergoing vascular surgery) (13). Moreover, the elevation in cTns has been demonstrated to predict short- and long-term prognosis in most studies (Tab. I) (12,14-27).

In the study by Higham et al, the correlation between cTns and future cardiac events was not statistically significant when authors considered cTnT, while cTnI maintained its one-year predictive power (23). Also in the study by Filipovic et al, elevations in cTn didn’t correlate with one-year cardiac mortality, but the analysis excluded those patients who died in the first 30 postoperative days (22). When the whole population was included in the analysis, the correlation resulted significant (p<0.0001) (17). Inter-study discrepancies may depend on the difference in cTns cut-off, enrolled population, type of surgery length of follow-up, and in the definition of cardiac end-points.

**PATHOPHYSIOLOGY OF PERIOPERATIVE MI**

Atherosclerosis is the common substrate of almost every MI, but the trigger is the formation of a luminal thrombus on a ruptured/fissured atherosclerotic plaque. Acute coronary syndromes presenting with ST-segment elevation are determined by an occlusive luminal thrombus, while non ST-segment elevation acute coronary syndromes present a non-occlusive thrombus.

Vessel spasm, microvascular dysfunction, a rise in myocardial oxygen consumption may also play a role in acute coronary syndromes (28-30). The pathophysiology of perioperative MI is more complex because during and after surgery, unlike the nonsurgical setting, many alterations in homeostasis may favor or initiate the ischemic cascade itself. This aspect may have important management implications.

In the perioperative period, metabolic factors sec-
Conflicting evidence emerges from angiographic and autopic studies which have been conducted to better clarify the pathophysiology of perioperative MI (35-37): the non-homogeneous characteristics of the populations enrolled and the lack of standardization of cardiac events may in part explain those differences.

The relative role of fixed coronary artery stenoses and plaque thrombosis in the pathophysiology of perioperative MIs is not clear.
TABLE II - FACTORS WHICH MAY DETERMINE PERIOPERATIVE MYOCARDIAL ISCHEMIA AND MYOCARDIAL INFARCTION

| Reduction of myocardial oxygen supply | Increase of myocardial oxygen's requirement |
|--------------------------------------|---------------------------------------------|
| Ipoxemia                             | Increased myocardial wall stress            |
| changes in pulmonary function        | hypervolemia                                |
| weaning from the ventilator          | rise in blood pressure                      |
|                                     | rise in end-diastolic left-ventricular pressure |
| Reduced blood pressure               | Arhythmias                                  |
| left ventricular dysfunction         | elevation in plasma catecholamines          |
| hypovolemia                          | withdrawal of β-blockers                    |
| systemic vasodilatation              | hypotension                                 |
|                                     | postoperative pain                          |
| Coronary vasospasm                   | Changes in body temperature                 |
| Endoluminal thrombosis               |                                             |
| enhanced platelet aggregation        |                                             |
| hypercoagulability                   |                                             |
| impaired fibrinolysis                 |                                             |

TABLE III - ESTIMATION OF PERIOPERATIVE CARDIAC RISK ACCORDING TO THE "REVISED CARDIAC RISK INDEX" (38)

| Risk factors n° | Major cardiac complications * |
|-----------------|------------------------------|
| 0               | 0.4 %                        |
| 1               | 1.1 %                        |
| 2               | 4.6 %                        |
| ≥ 3             | 9.7 %                        |

Risk factors: high-risk surgery (abdominal aortic aneurysm, thoracic, abdominal); ischemic heart disease; heart failure; cerebrovascular disease; insulin-treated diabetes; creatinine > 177 µmol/L.

* myocardial infarction, pulmonary edema, primary cardiac arrest, complete heart block

Clinical indices

Clinical indices are derived from statistical analysis of a data-base of thousands of patients and assign a specific score according to the weight given to each cardiac risk factor (8, 38-42). The best validated among those indices is the “Revised Cardiac Risk Index” by Lee et al (Tab. III) (38).

The advantages of risk indices are the simplicity and the precision in risk stratification, although the main limitation is the lack of indications for perioperative management, particularly supplemental preoperative testing and prophylactic therapy.

Guidelines

The American College of Cardiology (ACC)/American Heart Association (AHA) and American College of Physicians (ACP) guidelines were developed in order to guide physicians in perioperative management. They suggest consensus-derived algorithms which allow preoperative cardiac risk assessment, patient’s information and clinical decision making about perioperative diagnostic testing, monitoring, and therapy (1, 43, 44).

ACP guidelines are based on Detsky’s “Modified Cardiac Risk Index” (42), while ACC/AHA guidelines derive from the interpretation of data from various studies by a specific Task Force.

The overriding theme of the ACC/AHA guidelines is
that intervention is rarely required to lower the perioperative cardiac risk unless such intervention is indicated irrespective of the surgical context (1).

The nature of the surgical disease must be also considered. In case of urgent surgery, preoperative evaluation should be rapid, so as not to delay the operation, while a more precise evaluation can be conducted soon after surgery.

Sometimes an extensive workup may add significant delays to surgery without adding any further advantage and with possible, heavy consequences in certain groups of patients, for example those affected by cancer and waiting for life-saving operations.

Extensive and redundant preoperative cardiac evaluation can also result in morbidity, higher costs and refusal to undergo surgery (45).

The stepwise approach is based on the definition of the patient’s clinical status and the surgery’s cardiac risk (Tabs. IV and V). Supplemental testing should be performed only if it is likely to influence the patient’s treatment and outcome (1).

Unlike ACP guidelines, which have never been validated prospectively, some studies have demonstrated that application of the ACC/AHA guidelines in daily clinical practice may help physicians in risk stratification, may reduce hospital length of stay and costs, and may improve prognosis (26, 46-50).

However, Bursi et al have recently demonstrated that despite a rigorous implementation of ACC/AHA algorithms, patients undergoing major vascular surgery still remain at high risk of perioperative cardiac events (26).

In particular, among clinically stable patients who had undergone coronary revascularization in the last 5 years, about 50% had a postoperative elevation in cTnI and the event-free survival at 30 days was as high as 72% (26).

According to the recommendations of the ACC/AHA guidelines, those patients were scheduled for surgery without any supplemental tests, but this strategy may have underestimated the real cardiovascular risk (1, 26, 51).

Some authors suggest that the stepwise approach of the ACC/AHA guidelines, based on a detailed clinical evaluation with selective use of supplemental testing may be of limited use in some circumstances, for a variety of reasons (51).

First of all, ACC/AHA guidelines are founded on observational data obtained several years ago, when perioperative care was different and cTns analysis was not available. As a consequence, the real incidence of perioperative MIs and the efficacy of preventive strategy may have been underestimated.

Moreover, the current ACC/AHA guidelines state that in the presence of favorable stress test within the last two years and stable symptoms, patients can undergo surgery: this time span is probably too long.

A procedure of coronary revascularization in the previous 5 years doesn’t warrant a favorable outcome. This may be due to an incomplete/failed revascularization or a progression of atherosclerotic disease in grafts or in native vessels.

Silent ischemia and limited functional capacity may mask high-risk features if the clinical evaluation is limited to history and physical examination. Therefore, noninvasive screening may unmask high-risk situations in some subgroups of patients and in some types of surgery, independent of clinical history.

Noninvasive testing for myocardial ischemia

In a large number of surgical patients, noninvasive testing plays an important role in defining the risk profile.

In general, both exercise and pharmacological stress testing have a high negative predictive power (90-100%) and a non-uniform but generally low positive predictive power (6-67%) (2).

Results from a meta-analysis that compared the prognostic accuracy of 6 noninvasive tests suggest a superiority of echo-dobutamine in predicting postoperative cardiac events (cardiac death and nonfatal MI) (52).

These data call for cautious interpretation because of the limitations which emerge from many studies: weak methods, low event-rate, heterogeneity across the results for individual test, dichotomized (positive or negative) compared to semiquantitative (extent of reversibility of myocardial defect) results, the nearly exclusive application to vascular surgery patients which precludes broad generalizations to other surgical settings.

Besides the ischemic threshold, noninvasive tests may investigate different parameters: an ergometric test can determine the functional capacity, while echo-dobutamine may assess hemodynamic parameters and
valvular function (1). Moreover, pharmacological testing may be the sole option in patients with severe exercise restrictions.

Moreover, in the absence of definitive data about the efficacy of the different noninvasive testing, the consultant should consider that the availability and the local expertise in diagnosing coronary artery disease is more important than the particular type of test (1).

**Coronary angiography**

Coronary angiography should be prescribed on the basis of the results of noninvasive testing, while for certain categories of patients with baseline high cardiac risk, diagnostic cardiac catheterization may be performed without any previous noninvasive testing.

Recommendations for preoperative coronary angiography don’t differ from those for the nonsurgical setting published by ACC/AHA (1, 53).

**PREVENTION OF PERIOPERATIVE MI**

Different prophylactic strategies have been tested in order to reduce the incidence of ischemic events after noncardiac surgery.

The cornerstones of preventive strategy are adrenergic modulation, atherosclerotic plaque stabilization, and coronary artery revascularization.

Given the complex and multifactorial pathophysiology of perioperative MI, a relative risk reduction of more than 35% by a single intervention is unlikely (1).

**β-blockers**

β-blockers enhance coronary flow, reduce myocardial oxygen consumption by modulation of systemic blood pressure, heart rate and contractility, and have anti-arrhythmic effects.

Although earlier studies have documented a beneficial effect in patients treated with β-blockers in the perioperative period (54,55), results from recent meta-analysis are controversial (56-58).

Such a discrepancy may probably depend on various reasons: the inadequate statistical power and the lack of randomization in several studies; the lack of pre-defined target heart rate (usually, about 60 beats/min); the paucity of data about patients at low to intermediate cardiac risk; the lack of comparison studies between different molecules and different routes of administration (intravenous vs oral agents).

A recent, retrospective, and very large observational study compared the in-hospital outcome of patients receiving β-blocker therapy and those not treated with β-blockers (59). All patients underwent major noncardiac surgery and were matched according to the Revised Cardiac Risk Index (38).

Surprisingly, perioperative β-blockade wasn’t associated with an overall reduced mortality, although a step gradient in treatment effect was observed in relation to the Revised Cardiac Risk Index score (59). β-blocker use was associated with increased mortality among low-risk patients, was neutral among intermediate-risk patients and had a beneficial effect in high-risk patients (59).

According to the results of the few studies and the

---

**TABLE IV - CLINICAL PREDICTORS OF INCREASED PERIOPERATIVE CARDIOVASCULAR RISK (MYOCARDIAL INFARCTION, HEART FAILURE, DEATH) (1)**

| Major                          | Intermediate                          | Minor                        |
|--------------------------------|---------------------------------------|------------------------------|
| Acute coronary syndromes      | Mild angina (Canadian class I/II)     | Advanced age                 |
| • acute (< 7 days) or recent (7-30 gg) myocardial infarction with evidence of important ischemic risk by clinical symptoms or non-invasive studies | Previous myocardial infarction    | Abnormal electrocardiogram   |
| • unstable or severe angina (Canadian class III/IV) | Compensated or previous heart failure | (left bundle-branch block, left ventricular hypertrophy, ST-T abnormalities) |
| Decompensated heart failure    | Diabetes mellitus (particularly insulin-dependent) | Rhythm other than sinus       |
| Significant arrhythmias        | Renal insufficiency                   | Reduced functional capacity   |
| • high-grade atrioventricular block |                                      | History of stroke            |
| • symptomatic ventricular arrhythmias in the presence of underlying heart disease |                                      | Uncontrolled hypertension     |
| • supraventricular arrhythmias with uncontrolled heart rate |                                      |                              |
| Severe valvular disease        |                                      |                              |

---
opinions of some authors, the use of β-blockers should be at present limited to high-risk patients undergoing major noncardiac surgery.

No data are available for short-stay procedures and for minor operations.

Until the results from two ongoing randomized trials (POISE, DECREASE IV) on the efficacy of β-blockers are available (60,61), we suggest that physicians in charge and consultants refer to the recently updated ACC/AHA guidelines about perioperative β-blocker therapy (62).

α2-adrenergic agonists

α2-adrenergic agonists may reduce perioperative cardiac events because they suppress the release of catecholamines.

A meta-analysis, which included 12 randomized controlled trials, demonstrated a beneficial effect of α2-adrenergic agonists in reducing mortality (RR: 0.47; 95%CI: 0.25-0.90) and myocardial infarction (RR: 0.66; 95%CI: 0.46-0.94) in patients undergoing vascular surgery (63).

This trend was confirmed by another meta-analysis (57) and by one subsequent randomized study which compared clonidine with placebo in 190 patients undergoing non-cardiac surgery, with or at risk for atherosclerotic disease (64). In the latter study, clonidine was significantly associated with a reduced incidence of ischemic events (14% vs 31%; p = 0.01) and reduced two-year mortality (15% vs 29%; RR: 0.43; 95% CI 0.21-0.89; p = 0.035) (64).

Although the results of randomized trials and meta-analysis on α2-adrenergic agonists are encouraging, they should be confirmed by large, randomized and well powered trials.

Other anti-ischemic agents

At the moment, no definitive data support the administration of calcium-channel blockers or nitrates (57), although a meta-analysis has demonstrated a benefit of calcium-channel blockers, particularly diltiazem, in reducing the risk of supraventricular arrhythmias, ischemia or the combined end-points of death, myocardial infarction, supraventricular arrhythmias, heart failure (65).

Statins

Statin therapy may reduce perioperative cardiac events through stabilization of coronary atherosclerotic plaques and anti-thrombotic and anti-inflammatory effects. Their efficacy has been demonstrated in several primary and secondary prevention studies conducted in nonoperative setting.

Data about the efficacy of perioperative statin therapy derive from some observational studies (66-68) and one small randomized trial (69): they showed a significant reduction of cardiac mortality and morbidity in the statin-treated group.

However, in the absence of evidence of a broad benefit of perioperative statins, they should be given only in those patients already assuming them as home-therapy or as new prescription in patients who meet the classical indications for the nonsurgical setting (70, 71).

Coronary revascularization

Flow-limiting coronary stenoses play an important role in the pathogenesis of perioperative MI.

Therefore, surgical or percutaneous coronary revascularization may help in preventing ischemic complications. However, perioperative MIs frequently develop at the site of non-severe stenoses.

The available evidence on the overall benefit of coro-
nary revascularization (particularly coronary bypass surgery) derive from few retrospective studies and from one randomized clinical trial which compared coronary revascularization with medical therapy in stable patients with a coronary anatomy suitable for revascularization, undergoing major vascular surgery (72-74).

Taken together, these results suggest that prophylactic coronary revascularization is of little or no benefit before noncardiac surgery.

It must also be considered that specific data relative to patients with very high-risk conditions (unstable angina, severely depressed left ventricular function, aortic stenosis...) are lacking because those categories of patients have been excluded from any analysis or randomization.

Moreover, when planning preoperative coronary revascularization, the relative benefit should be weighed against the inevitable risk and the delay related to the procedure itself (either surgical or percutaneous) (75, 76).

The time-delay attributable to coronary revascularization may be unacceptable in certain subgroups of patients, such as those waiting for urgent surgery (1, 70).

Noncardiac surgery may be performed as soon as two weeks after balloon angioplasty, about one month after coronary artery bypass surgery, and at least six weeks after positioning of a bare metal stent (70, 77).

Preoperative implantation of a drug-eluting stent is not indicated because the need for long-term, double anti-platelet therapy contrasts with the surgery-specific hemorrhagic risk.

In conclusion, the indication for surgical or percutaneous coronary revascularization of the ACC/AHA practice guidelines on perioperative cardiovascular evaluation for noncardiac surgery are essentially identical to those for the nonoperative setting (78, 79). As a consequence, the decision to revascularize just to lower the cardiac risk of noncardiac surgery is appropriate only in a small subset of high-risk patients (1).

**POSTOPERATIVE MONITORING AND MANAGEMENT**

Given the silent and subtle nature of perioperative myocardial ischemia, postoperative monitoring is needed in order to promptly identify acute ischemic events.

Unresolved issues in monitoring strategy are which diagnostic test to perform, for how long, and in which patients.

ACC/AHA recommendations (1) for postoperative monitoring include the execution of 12-lead ECGs soon after surgery and on postoperative days 1 and 2 in patients with intermediate/major cardiac risk predictors who have undergone intermediate to high-risk operations.

On postoperative days 1 and 4 (or at hospital discharge, whichever comes first) plasma levels of cTnI should be measured (1).

Continuous ST-segment monitoring in patients affected by ischemic heart disease and/or undergoing high-risk surgery may enhance sensitivity to detect perioperative myocardial ischemia (1). However, in certain subgroups of patients at low cardiac risk, the specificity of ST-segment changes is questionable.

No randomized clinical trial has specifically evaluated the optimal medical strategy in patients with perioperative MI. Therefore, it seems reasonable to correct eventual precipitating factors (for example, hypoxia) and to administer those therapies which have been demonstrated to be effective in nonoperative MI (ACE-inhibitors, statins, β-blockers).

Given the high bleeding risk at the surgical site, great caution should be used when considering aggressive anticoagulant and antiplatelet therapy. In the absence of definitive data from randomized clinical trials, the risk of bleeding must be weighed against the risk of suboptimal therapy.

Thrombolytic therapy has been demonstrated to reduce mortality in ST-segment elevation MI unrelated to surgery, but recent noncardiac surgery is a strong contraindication to thrombolytic therapy.

When angiography and revascularization may be rapidly performed, reperfusion therapy with primary coronary angioplasty may be the first choice in ST-segment elevation MI (1).

Early coronary angiography with eventual coronary revascularization is also a valid option in patients with non-ST-elevation acute coronary syndromes with high-risk features and who are able to take antiplatelet and anticoagulant therapy (1).

Long-term management and secondary prevention should include evaluation for left ventricular function, residual ischemia and electrical instability, strict control...
REFERENCES

1. Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to update the 1996 guidelines on perioperative cardiovascular evaluation for noncardiac surgery). Circulation 2002; 105: 1257-67.

2. Devereaux PJ, Goldman L, Cook DJ, Gilbert K, Leslie K, Guyatt HG. Perioperative cardiac events in patients undergoing noncardiac surgery: A review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ 2005; 173: 627-34.

3. Sprung J, Warner ME, Contreras MG, et al. Predictors of survival following cardiac arrest in patients undergoing noncardiac surgery: A study of 518, 294 patients at a tertiary referral center. Anesthesiology 2003; 99: 259-69.

4. Mangano DT, Browner WS, Hollenberg M, London MJ, Tubau JF, Tateo IM, and the study of perioperative ischemia research group. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. N Engl J Med 1990; 323; 1781-8.

5. Ashton CM, Petersen NJ, Wray NP, et al. The incidence of perioperative myocardial infarction in men undergoing noncardiac surgery. Ann Intern Med 1993; 118: 504-10.

6. Shah KB, Kleinman BS, Rao TL, Jacobs HK, Mestan K, Shaafsma M. Angina and other risk factors in patients with cardiac diseases undergoing noncardiac operations. Anesth Analg 1990; 70: 240-7.

7. Badner NH, Knill RL, Brown JE, Novick TV, Gelb AW. Myocardial infarction after noncardiac surgery. Anesthesiol-
8. Kumar R, McKinney WP, Raj G, et al. Adverse cardiac events after surgery: Assessing risk in a veteran population. J Gen Intern Med 2001; 16: 507-18.
9. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined - A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J 2000; 21: 1502-13.
10. Lucreziotti S, Foroni C, Fiorentini C. Perioperative myocardial infarction in noncardiac surgery: The diagnostic and prognostic role of cardiac troponins. J Intern Med 2002; 252: 11-20.
11. Mangano DT. Beyond CK-MB. Biochemical markers for perioperative myocardial infarction. Anesthesiology 2004; 81: 1317-20.
12. Adams JE III; Sicard GA, Allen BT, et al. Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I. N Engl J Med 1994; 330: 670-4.
13. Mangano DT. Perioperative cardiac morbidity. Anesthesiology 1990; 72: 153-84.
14. Lee TH, Thomas EJ, Ludwig LE, et al. Troponin T as a marker for myocardial ischemia in patients undergoing major noncardiac surgery. Am J Cardiol 1996; 77: 1031-6.
15. Lopez-Jimenez F, Goldman L, Sacks DB, et al. Prognostic value of cardiac troponin T after noncardiac surgery: 6-month follow-up data. J Am Coll Cardiol 1997; 29: 1241-5.
16. Oscarsson A, Eintrei C, Anskar S, et al. Troponin T-values provide long-term prognosis in elderly patients undergoing non-cardiac surgery. Acta Anaesthesiol Scand 2004; 48: 1071-9.
17. Filipovic M, Jeger R, Probst C, et al. Heart rate variability and cardiac troponin I are incremental and independent predictors of one-year all-cause mortality after major noncardiac surgery in patients at risk of coronary artery disease. J Am Coll Cardiol 2003; 42: 1767-76.
18. Kim LJ, Martinez EA, Faraday N, et al. Cardiac troponin I predicts short-term mortality in vascular surgery patients. Circulation 2002 106: 2366-71.
19. Kertai MD, Boersma E, Klein J, van Urk H, Bax JJ, Poldermans D. Long-term prognostic value of asymptomatic cardiac troponin T elevations in patients after major vascular surgery. Eur J Vasc Endovasc Surg 2004; 28: 59-66.
20. Landesberg G, Shatz V, Akopnik I, et al. Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery. J Am Coll Cardiol 2003; 42: 1547-54.
21. Le Manach Y, Perel A, Coriat P, Godef G, Bertrand, Riou B. Early and delayed myocardial infarction after abdominal aortic surgery. Anesthesiology 2005; 102: 885-91.
22. Filipovic M, Jeger RV, Girard T, et al. Predictors of long-term mortality and cardiac events in patients with known or suspected coronary artery disease who survive major non-cardiac surgery. Anaesthesia 2005; 60: 5-11.
23. Higham H, Sear JW, Sear YM, Kemp M, Hooper RJL, Foex P. Peri-operative troponin I concentration as a marker of long-term postoperative adverse cardiac outcomes - A study in high-risk surgical patients. Anaesthesia 2004; 59: 318-23.
24. Rapp HJ, Rabethge S, Luiz T, Haux P. Perioperative ST-segment depression and troponin T release. Identification of patients with highest risk for myocardial damage. Acta Anaesthesiol Scand 1999; 43: 124-9.
25. Vikenes K, Andersen KS, Farstad M, Nordrehaug JE. Temporal pattern of cardiac troponin I after thoracotomy and lung surgery. Int J Cardiol 2004; 96: 403-7.
26. Bursi R, Bubin L, Barbieri A, et al. Vascular surgery patients: Perioperative and long-term risk according to the ACC/AHA guidelines, the additive role of post-operative troponin elevation. Eur Heart J 2005; 26: 2448-56.
27. Jules-Elysee K, Urban MK, Urquhart B, Milman S. Troponin I as a diagnostic marker of a perioperative myocardial infarction in the orthopedic population. J Clin Anesthet 2001; 13: 556-60.
28. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. Part 1. N Engl J Med 1992; 326: 242-50.
29. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. Part 2. N Engl J Med 1992; 326: 310-8.
30. Braunwald E. Unstable angina: An etiologic approach to management. Circulation 1998; 98: 2219-22.
31. Shoemaker WC, Appel PL, Kram HB. Tissue oxygen debt as a determinant of lethal and nonlethal postoperative organ failure. Crit Care Med 1988; 16: 1117-20.
32. Mahdy AM, Galley HF, Abdel-Wahed Ma, el Korny KF, Sheta SA, Webster NR. Differential modulation of interleukin-6 and interleukin-10 by diclofenac in patients undergoing major surgery. Br J Anaesth 2002; 88: 797-802.
33. McDaniel MD, Pearce WH, Yao JS, et al. Sequential changes in coagulation and platelet function following femorotibial bypass. J Vasc Surg 1984; 1: 261-8.
34. Breslow MJ, Parker SD, Frank SM, et al. Determinants of catecholamine and cortisol responses to lower extremity revascularization. PIRAT Study Group. Anesthesiology 1993; 79: 1202-9.
35. Dawood MM, Gupta DK, Southern J, Walaia A, Atkinson JB, Eagle KA. Pathology of fatal perioperative myocardial infarction: Implications regarding pathophysiology and prevention. Int J Cardiol 1996; 57: 37-44.
36. Cohen MC, Aretz TH. Histological analysis of coronary artery lesions in fatal postoperative myocardial infarction.
Myocardial infarction and noncardiac surgery

Cardiovasc Pathol 1999; 8: 133-9.
37. Ellis SG, Hertzr NR, Young JR, Brener S. Angiographic correlates of cardiac death and myocardial infarction complicating major nonthoracic vascular surgery. Am J Cardiol 1996; 77: 1126-8.
38. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100: 1043-9.
39. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med 1977; 297: 845-50.
40. Larsen SF, Olesen KH, Jacobsen E, et al. Prediction of cardiac risk in non-cardiac surgery. Eur Heart J 1987; 8: 179-85.
41. Gilbert K, Laroque BJ, Patrick LT. Prospective evaluation of noncardiac risk indices for patients undergoing noncardiac surgery. Ann Intern Med 2000; 133: 356-9.
42. Detsky AS, Abrams HB, McLaughlin JR, et al. Predicting cardiac complications in patients undergoing non-cardiac surgery. J Gen Intern Med 1986; 1: 211-9.
43. American College of Physicians. Guidelines for assessing and managing the perioperative risk from coronary artery disease associated with major noncardiac surgery. Ann Intern Med 1997; 127: 309-12.
44. Palda VA, Detsky AS. Perioperative assessment and management of risk from coronary artery disease. Ann Intern Med 1997; 127: 313-28.
45. Krupski WC, Nehler MR, Whitehill TA, Lawson RC, Streeker PK, Hiatt WR. Negative impact of cardiac evaluation before vascular surgery. Vascular Medicine 2000; 5: 3-9.
46. Almanaseer Y, Mukherjee D, Kleine-Rogers EM, et al. Implementation of the ACC/AHA guidelines for perioperative cardiac risk assessment in a general medicine preoperative clinic: Improving efficiency and preserving outcomes. Cardiology 2005; 103: 24-9.
47. Froelich JB, Karavitie D, Russman PL, et al. American College of Cardiology/American Heart Association preoperative assessment guidelines reduce resource utilization before aortic surgery. J Vasc Surg 2002; 36: 758-63.
48. Licker M, Khatchatourian G, Schweizer G, et al. The impact of a cardioprotective protocol on the incidence of cardiac complications after aortic abdominal surgery. Anesth Analg 2002; 95: 1525-33.
49. Samain E, Farah E, Leseche G, Marty J. Guidelines for perioperative cardiac evaluation from the American College of Cardiology/American Heart Association task force are effective for stratifying cardiac risk before aortic surgery. J Vasc Surg 2000; 31: 971-9.
50. Back MR, Schmacht DC, Bowser AN, et al. Critical appraisal of cardiac risk stratification before elective vascular surgery. Vasc Endovascular Surg 2003; 37: 387-97.
51. Hoeks SE, Bax JJ, Poldermans D. Should the ACC/AHA guidelines be changed in patients undergoing vascular surgery? Eur Heart J 2005; 26: 2358-60.
52. Kertai MD, Boersma E, Bax JJ, et al. A meta-analysis comparing the prognostic accuracy of six diagnostic tests for predicting perioperative cardiac risk in patients undergoing major vascular surgery. Heart 2003; 89: 1327-34.
53. Scanlon PJ, Faxon DP, Audet AM, et al. ACC/AHA guidelines for coronary angiography: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on coronary angiography). Developed in collaboration with the Society for Cardiac Angiography and Interventions. J Am Coll Cardiol 1999; 33: 1756-824.
54. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999; 341: 1789-94.
55. Mangano DT, Layung EL, Wallace, Tatoe I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996; 335: 1713-20.
56. Auerbach AD, Goldman L. Beta-blockers and reduction of cardiac events in noncardiac surgery: Scientific review. JAMA 2002; 87: 1435-44.
57. Stevens RD, Burri H, Tramer MR. Pharmacologic myocardial protection in patients undergoing noncardiac surgery: A quantitative systematic review. Anesth Analg 2003; 7: 623-33.
58. Devereaux PJ, Beattie WS, Choi PT, et al. How strong is the evidence for the use of perioperative beta-blockers in noncardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ 2005; 331: 313-21.
59. Lindenauger PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin E. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 2005; 353: 349-61.
60. Devereaux PJ, Yusuf S, Yang H, Choi PT, Guyatt GH. Are the recommendations to use perioperative beta-blocker therapy in patients undergoing noncardiac surgery based on reliable evidence? CMAJ 2004; 171: 245-7.
61. Schouten O, Poldermans D, Visser L, et al. Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: Rationale and design of the DECREASE-IV study. Am Heart J 2004; 148: 1047-52.
62. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: Focused update on perioperative beta-blocker therapy: A report of the American College of Cardiology/American Heart Association.
Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society for Vascular Medicine and Biology. J Am Coll Cardiol 2006; 47: 2343-55.

63. Wijesundera DN, Naik JS, Beattie WS. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: A meta-analysis. Am J Med 2003; 114: 742-52.

64. Wallace AW, Galindez D, Salahich A, et al. Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery. Anesthesiology 2004; 101: 284-93.

65. Wijesundera DN, Beattie WS. Calcium channel blockers for reducing cardiac morbidity after noncardiac surgery: A meta-analysis. Anesth Analg 2003; 97: 634-41.

66. Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA 2004; 291: 2092-9.

67. O’Neil-Callahan K, Katsimaglis G, Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: The Statins for Risk reduction in Surgery (StaRRS) study. J Am Coll Cardiol 2005; 45: 336-42.

68. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003; 107: 1848-51.

69. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: A randomized trial. J Vasc Surg 2004; 39: 967-75.

70. Auerbach A, Goldman L. Assessing and reducing the cardiac risk of noncardiac surgery. Circulation 2006; 113: 1361-76.

71. Grundy SM, Cleeman JL, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.

72. Eagle KA, Rihal CS, Mickel MC, Holmes DR, Foster ED, Gersh BJ. Cardiac risk of noncardiac surgery: Influence of coronary artery disease and type of surgery in 3368 operations: CASS Investigators and University of Michigan Heart Care Program, Coronary Artery Surgery Study. Circulation 1997; 96: 1882-7.

73. Hassan SA, Hlatky MA, Boothroyd DB, et al. Outcomes of noncardiac surgery after coronary bypass surgery or coronary angioplasty in the Bypass Angioplasty Revascularization Investigation (BARI). Am J Med 2001; 110: 260-6.

74. McFalls EO, Ward HB Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med 2004; 351: 2795-804.

75. Kaluza GL, Joseph J, Lee JR, Raizner ME, Raizner AE. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol 2000; 35: 1288-94.

76. Brilakis ES, Orford JL, Fasseas P, et al. Outcome of patients undergoing balloon angioplasty in the two months prior to noncardiac surgery. Am J Cardiol 2005; 96: 512-4.

77. Devereaux PJ, Goldman L, Yusuf S, Gilbert K, Leslie K, Guyatt GH. Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: a review. CMAJ 2005; 173: 779-88.

78. Smith SC Jr, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: e166-286.

79. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110: 1168-76.